CoChat

Dynamic monitoring of beating periodicity of stem cell‐derived cardiomyocytes as a predictive tool for preclinical safety assessment

Open access
Abassi, Yama A, Xi, Biao, Li, Nan, Ouyang, Wei, Seiler, Alexander, Watzele, Manfred, Kettenhofen, Ralf, Bohlen, Heribert, Ehlich, Andreas, Kolossov, Eugen, Wang, Xiaobo, Xu, Xiao · 2012 · British Journal of Pharmacology
Cited by 124

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND PURPOSE Cardiac toxicity is a major concern in drug development and it is imperative that clinical candidates are thoroughly tested for adverse effects earlier in the drug discovery process. In this report, we investigate the utility of an impedance‐based microelectronic detection system in conjunction with mouse embryonic stem cell‐derived cardiomyocytes for assessment of compound risk in the drug discovery process. EXPERIMENTAL APPROACH Beating of cardiomyocytes was measured by a recently developed microelectronic‐based system using impedance readouts. We used mouse stem cell‐derived cardiomyocytes to obtain dose‐response profiles for over 60 compounds, including ion channel modulators, chronotropic/ionotropic agents, hERG trafficking inhibitors and drugs known to induce Torsades de Pointes arrhythmias. KEY RESULTS This system sensitively and quantitatively detected effects of modulators of cardiac function, including some compounds missed by electrophysiology. Pro‐arrhythmic compounds produced characteristic profiles reflecting arrhythmia, which can be used for identification of other pro‐arrhythmic compounds. The time series data can be used to identify compounds that induce arrhythmia by complex mechanisms such as inhibition of hERG channels trafficking. Furthermore, the time resolution allows for assessment of compounds that simultaneously affect both beating and viability of cardiomyocytes. CONCLUSIONS AND IMPLICATIONS Microelectronic monitoring of stem cell‐derived cardiomyocyte beating provides a high throughput, quantitative and predictive assay system that can be used for assessment of cardiac liability earlier in the drug discovery process. The convergence of stem cell technology with microelectronic monitoring should facilitate cardiac safety assessment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01623.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 124

Metadata

Authors
Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., Kettenhofen, R., Bohlen, H., Ehlich, A., Kolossov, E., Wang, X., & Xu, X.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2012-02-10
Volume
165
Issue
5
Pages
1424-1441
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1748447088
Cited by
124
References
4
FWCI
5.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dynamic monitoring of beating periodicity of stem cell‐derived cardiomyocytes as a predictive tool for preclinical safety assessment. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01623.x
The paper
Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., Kettenhofen, R., Bohlen, H., Ehlich, A., Kolossov, E., Wang, X., & Xu, X. (2012). Dynamic monitoring of beating periodicity of stem cell‐derived cardiomyocytes as a predictive tool for preclinical safety assessment. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01623.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.